West Virginia 2025 Regular Session

West Virginia House Bill HB2861

Introduced
2/24/25  

Caption

Mental Health and Substance Use Disorders Insurance Coverage Protection Act

Summary

HB2861 would create the “Mental Health and Substance Use Disorders Insurance Coverage Protection Act” and require certain West Virginia health insurance policies, plans, and contracts issued or renewed on or after January 1, 2026, to cover medically necessary treatment for mental health and substance use disorders. The bill applies to a range of insurance lines, including public employees insurance, individual and group accident and sickness policies, hospital and medical service corporations, health care corporations, and HMOs. It defines key terms such as “medically necessary treatment,” “generally accepted standards of care,” “utilization review,” and “utilization review criteria,” and directs insurers to base coverage decisions on recognized clinical standards and evidence-based sources. The bill also limits insurer practices in several ways. It prohibits insurers from restricting coverage for chronic or pervasive conditions to short-term or acute treatment only, requires coverage decisions to follow generally accepted standards, and bars insurers from using discretionary contract clauses that could lead to deferential judicial review. If in-network services are unavailable within geographic and timeliness standards, insurers must arrange out-of-network coverage at in-network cost-sharing levels. The bill further prevents insurers from denying medically necessary services on the theory that they should be covered by public programs such as Medicaid, Medicare, SSI, SSDI, or special education, and authorizes the Insurance Commissioner to impose civil penalties for violations.

Impact

HB2861 would amend multiple sections of West Virginia insurance law and add a new article to Chapter 33, creating enforceable coverage standards for mental health and substance use disorder treatment. It would require insurers and related entities performing utilization review to use current, generally accepted clinical criteria, provide training and transparency around those criteria, and maintain interrater reliability standards for review decisions. It would also void discretionary authority clauses in insurance contracts issued or renewed on or after January 1, 2026, if those clauses could create a deferential standard of review. The bill would affect insurers, managed care organizations, public employee plans, providers, and insured individuals by expanding coverage obligations and limiting denial practices. It gives the Insurance Commissioner enforcement authority, including civil penalties of up to $5,000 per violation or $10,000 for willful violations, and applies to both insurers and entities acting on their behalf.

Sentiment

Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the measure appears to be framed as a consumer-protection and parity bill intended to strengthen access to behavioral health care. Its sponsors present it as a coverage and standards bill rather than a cost-control measure, suggesting a generally supportive policy posture toward expanded mental health and addiction treatment access. No recorded floor or committee vote history is provided here, so there is no documented opposition or support from debate to assess. The overall tone of the legislation is pro-coverage and pro-enforcement, with a strong emphasis on clinical standards, parity, and insurer accountability.

Contention

The main points of contention likely concern insurer discretion, cost, and administrative burden. Insurers may object to being required to follow external clinical guidelines, to authorize the next higher level of care when the preferred placement is unavailable, to provide out-of-network coverage at in-network cost-sharing, and to eliminate discretionary clauses that can affect litigation standards. They may also view the interrater reliability testing, training, reporting, and penalty provisions as costly and operationally burdensome. On the other side, advocates for mental health and addiction treatment access would likely support these provisions because they reduce denials, limit restrictive utilization review, and strengthen parity between behavioral health and other medical coverage. The bill’s explicit prohibition on shifting coverage to public entitlement programs may also be seen as important by patient advocates, while insurers may see it as limiting coordination of benefits and increasing claims exposure.

Companion Bills

No companion bills found.

Previously Filed As

WV SB1013

Prohibiting payment to residential substance use disorder treatment facilities in certain circumstances

WV HB113

Prohibiting payment to residential substance use disorder treatment facilities that do not meet certain requirements

WV HB116

Relating to authorizing the Public Employee Insurance Agency to provide insurance coverage for certain prescribed weight loss medications

WV SB1001

Supplementing and amending appropriations to Department of Health and Department of Human Services

WV HB101

Supplementing and amending appropriations to the Department of Health and Department of Human Services

WV HB115

Relating to the amount of surplus deposited into the Revenue Shortfall Reserve Fund and providing for an effective date

WV SB1015

Amending amount of surplus deposited into Revenue Shortfall Reserve Fund

WV SCR102

Extending State of Emergency and suspending certain requirements for Free Application for Federal Student Aid

WV SB1006

Making supplementary appropriation to Bureau for Medical Services, Policy and Programming, and to BOE

WV HB106

Making a supplementary appropriation to the Department of Human Services, Bureau for Medical Services – Policy and Programming and State Board of Education – State Department of Education

Similar Bills

CA AB1612

Disposition of controlled substances.

MA H2227

Replacing archaic and stigmatizing language for substance use

US HB830

SAFE Act Save Americans from the Fentanyl Emergency Act

MI HB4948

Controlled substances: other; sentencing guidelines for retail sale of products containing ephedrine or pseudoephedrine; modify. Amends sec. 13m, ch. XVII of 1927 PA 175 (MCL 777.13m). TIE BAR WITH: HB 4947'25

NJ S829

"CJ's Law"; Criminalizes manufacture, sale, and possession of substances containing kratom.

NJ A1617

"CJ's Law"; Criminalizes manufacture, sale, and possession of substances containing kratom.

NJ A1203

"CJ's Law"; Criminalizes manufacture and distribution of substances containing kratom under certain circumstances.

NJ S2271

"CJ's Law"; Criminalizes manufacture and distribution of substances containing kratom under certain circumstances.